已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and Safety of Endoscopic Through-the-Scope Suture System for Gastrointestinal Defects

医学 肌切开术 穿孔 外科 荟萃分析 粘膜切除术 梅德林 随机对照试验 内窥镜检查 内科学 贲门失弛缓症 食管 材料科学 政治学 法学 冲孔 冶金
作者
Muhammad Asif Aziz,Hossein Haghbin,Manesh Kumar Gangwani,Azizullah Beran,Dushyant Singh Dahiya,Hassam Ali,Amir Humza Sohail,Wade Lee‐Smith,Syed Uzair Hamdani,Faisal Kamal,Douglas G. Adler
出处
期刊:Journal of Clinical Gastroenterology [Lippincott Williams & Wilkins]
标识
DOI:10.1097/mcg.0000000000002019
摘要

Objective: Recently, a through-the-scope suturing (TTSS) system has received FDA approval and has been evaluated for closing mucosal defects postintervention. We hereby performed a systematic review and pooled meta-analysis of available studies to assess the safety and efficacy of this intervention. Methods: We queried the following databases through April 26, 2023: Embase, MEDLINE, Cochrane Central Register of Controlled Trials, and Web of Science Core Collection. Endoscopists utilizing TTSS for the following reasons were included: endoscopic mucosal resection, endoscopic submucosal dissection, peroral endoscopic myotomy, perforation, fistula closure, and/or stent fixation. The outcomes assessed were technical success, primary clinical success (closure of defect without additional intervention), and overall clinical success (closure of defect with/without additional intervention). Random effects model with the DerSimonian Laird approach was used to report event rates expressed as proportions with a 95% CI. Results: A total of 12 studies with 512 patients (mean age of 61.5 ± 18.4 y, 54.6% females) were included. The technical success rate was 96.0% (CI: 94.3%-97.7%). The primary clinical success rate was 74.8% (CI: 65.5%-84.1%). The overall clinical success rate was 95.4% (CI: 92.6-98.2%). Only 1 mortality case unrelated to intervention was reported. Conclusion: The TTSS appears safe and effective for closing mucosal defects after therapeutic endoscopic interventions. Further cost-effective studies should be performed comparing with endoclips for use in clinical settings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
林海完成签到 ,获得积分10
刚刚
松鼠完成签到 ,获得积分10
刚刚
笑点低的悒完成签到 ,获得积分20
1秒前
gstaihn完成签到,获得积分10
1秒前
aaa完成签到,获得积分10
3秒前
mr_beard完成签到 ,获得积分10
3秒前
顺心的采文完成签到,获得积分20
5秒前
ET完成签到,获得积分10
5秒前
景初柔发布了新的文献求助30
5秒前
寒冷哈密瓜完成签到 ,获得积分0
6秒前
小马甲应助moly采纳,获得10
6秒前
聪明勇敢有力气完成签到 ,获得积分10
7秒前
李家静完成签到 ,获得积分10
11秒前
DAYDAY完成签到 ,获得积分10
13秒前
Hello应助wfl采纳,获得10
14秒前
16秒前
雪莹完成签到,获得积分10
16秒前
沙沙完成签到 ,获得积分0
17秒前
想毕业的人完成签到,获得积分10
17秒前
大模型应助晨曦微露采纳,获得30
18秒前
18秒前
Weiming完成签到,获得积分20
21秒前
CHANG完成签到 ,获得积分10
21秒前
Bell发布了新的文献求助10
22秒前
秋作完成签到,获得积分10
23秒前
小凯完成签到 ,获得积分10
24秒前
魁梧的盼望完成签到 ,获得积分10
25秒前
木木杨发布了新的文献求助10
25秒前
xiuxiu完成签到 ,获得积分10
26秒前
30秒前
骆十八完成签到,获得积分10
33秒前
Bell完成签到,获得积分10
34秒前
木木杨完成签到,获得积分10
34秒前
激昂的逊发布了新的文献求助10
34秒前
可爱的函函应助HIBARRA采纳,获得10
34秒前
晨曦微露发布了新的文献求助30
37秒前
科研通AI5应助zhuhua采纳,获得10
38秒前
38秒前
38秒前
zho应助科研通管家采纳,获得10
38秒前
高分求助中
Mass producing individuality 600
Algorithmic Mathematics in Machine Learning 500
非光滑分析与控制理论 500
Разработка метода ускоренного контроля качества электрохромных устройств 500
A Combined Chronic Toxicity and Carcinogenicity Study of ε-Polylysine in the Rat 400
Advances in Underwater Acoustics, Structural Acoustics, and Computational Methodologies 300
NK Cell Receptors: Advances in Cell Biology and Immunology by Colton Williams (Editor) 200
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3827132
求助须知:如何正确求助?哪些是违规求助? 3369470
关于积分的说明 10456199
捐赠科研通 3089209
什么是DOI,文献DOI怎么找? 1699683
邀请新用户注册赠送积分活动 817443
科研通“疑难数据库(出版商)”最低求助积分说明 770239